Peter McPartland

CHAIN Biotechnology Ltd. develops new clostridium-based microbial technology for high value healthcare products. It produces novel 2nd generation live bio therapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD). The company was founded by Edward Green and Basil Omar in 2014 and is headquartered in Marlow, the United Kingdom.

CHAIN Biotechnology Ltd. develops new clostridium-based microbial technology for high value healthcare products. It produces novel 2nd generation live bio therapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD). The company was founded by Edward Green and Basil Omar in 2014 and is headquartered in Marlow, the United Kingdom.

CHAIN Biotechnology Ltd. develops new clostridium-based microbial technology for high value healthcare products. It produces novel 2nd generation live bio therapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD). The company was founded by Edward Green and Basil Omar in 2014 and is headquartered in Marlow, the United Kingdom.

CHAIN Biotechnology Ltd. develops new clostridium-based microbial technology for high value healthcare products. It produces novel 2nd generation live bio therapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD). The company was founded by Edward Green and Basil Omar in 2014 and is headquartered in Marlow, the United Kingdom.

CHAIN Biotechnology Ltd. develops new clostridium-based microbial technology for high value healthcare products. It produces novel 2nd generation live bio therapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD). The company was founded by Edward Green and Basil Omar in 2014 and is headquartered in Marlow, the United Kingdom.